HOME > BUSINESS
BUSINESS
- Daiichi Sankyo, GSK Agree to Set Up Joint Venture in Vaccine Business
March 5, 2012
- Novartis Most Admired Pharmaceutical Company in IAL Survey; Will “MR quality” Be Its Achilles’ Heel?
March 5, 2012
- ReproCELL to Change Model of Drug Discovery by Launching World’s 1st iPS Cell-derived Hepatocytes
March 5, 2012
- Sanofi-aventis Nichi-Iko Withholds NHI Price Listing of Authorized Allegra Generic in June
March 2, 2012
- Eisai President Naito Approves of Government Measures, Saying Japan’s Positioning “Improving Greatly”
March 2, 2012
- Pfizer Files Lawsuit Against Sandoz for Generic Lipitor, Sandoz to Contest Action
March 2, 2012
- Carna Biosciences Aiming to Out-License First Products to Megapharma in 2012 “if Possible”
March 2, 2012
- Medipal Group to Determine Profitability with Each Customer: Next President Shuichi Watanabe
March 2, 2012
- SBI to Enter Pharmaceutical Business Through Subsidiary, Considering Domestic Plant
March 1, 2012
- Takeda Initiates PIII Clinical Trials of Leuplin 6-Month Depot Formulation in Japan
March 1, 2012
- Takeda to Issue Straight Bonds for the First Time in 25 Years to Cover Nycomed Acquisition
March 1, 2012
- Takeda to Operate Global Vaccine Business, Aiming to Join Top 5 in 10 Years
March 1, 2012
- DSP to Acquire Boston Biomedical, US Bioventure Specializing in Oncology
March 1, 2012
- Nippon Kayaku Applies for Vascular Embolizing Agent NK939
March 1, 2012
- “It Is Time for Ranbaxy to Regain Brilliancy”: Daiichi Sankyo
February 29, 2012
- MTPC to Reorganize Product Marketing Dept. Aiming at Early Market Penetration of New Products
February 29, 2012
- Pfizer Japan to Set Up Rare Disease Division
February 29, 2012
- IMS Japan VP Miyoshi Calls for Focus Shift from Long-Listed Products to Abolishment of Post-Market Expansion Re-Pricing
February 29, 2012
- Major European, US Drug Makers Turning Sights Toward “Mini-buster” Drugs for Rare Diseases
February 29, 2012
- OTS102 Fails to Prolong Survival in Pancreatic Cancer: OncoTherapy Science
February 29, 2012
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…